GOVX Stock Overview
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GeoVax Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$9.75 |
| 52 Week Low | US$1.09 |
| Beta | 3.1 |
| 11 Month Change | 30.02% |
| 3 Month Change | 84.51% |
| 1 Year Change | -70.33% |
| 33 Year Change | -96.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08
GeoVax: Possible Vaccine Advancements In 2 Big Indications
Aug 08GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
Jul 28Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
Dec 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
Oct 03We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?
Feb 18GeoVax soars on NIAID grant for COVID-19 vaccine candidate
Jan 11Shareholder Returns
| GOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.4% | 3.4% | -2.4% |
| 1Y | -70.3% | 17.1% | 17.5% |
Return vs Industry: GOVX underperformed the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: GOVX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| GOVX volatility | |
|---|---|
| GOVX Average Weekly Movement | 35.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GOVX's share price has been volatile over the past 3 months.
Volatility Over Time: GOVX's weekly volatility has increased from 19% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 17 | David Dodd | www.geovax.com |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
GeoVax Labs, Inc. Fundamentals Summary
| GOVX fundamental statistics | |
|---|---|
| Market cap | US$12.94m |
| Earnings (TTM) | -US$27.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs GOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$22.33m |
| Gross Profit | -US$22.33m |
| Other Expenses | US$5.45m |
| Earnings | -US$27.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GOVX perform over the long term?
See historical performance and comparison